Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease

被引：0
作者：
Tatsuya Nitawaki
Yoshihiko Sakata
Kodai Kawamura
Kazuya Ichikado
机构：
[1] Saiseikai Kumamoto Hospital,Division of Respiratory Medicine
来源：
BMC Pulmonary Medicine | / 17卷
关键词：
Lung cancer; Non-small cell lung cancer; ALK; Alectinib; Interstitial lung disease; GGO;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 89 条
  • [1] Seto T(2013)CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study Lancet Oncol 14 590-598
  • [2] Kiura K(2003)FDA drug approval summary: Gefitinib (ZD1839) (Iressa®) tablets Oncologist 8 303-306
  • [3] Nishio M(2010)Noninfectious Pneumonitis after Everolimus therapy for advanced renal cell carcinoma Am J Respir Crit Care Med 182 396-403
  • [4] Nakagawa K(2015)Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib Investig New Drugs 33 1148-1150
  • [5] Maemondo M(2017)Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial Lancet 390 29-39
  • [6] Inoue A(2012)Drug induced interstitial lung disease Open Respir Med J 6 63-74
  • [7] Hida T(2015)Interstitial lung disease induced by alectinib (CH5424802 /RO5424802) Jpn J Clin Oncol 45 221-224
  • [8] Yamamoto N(2006)B and CTL responses to the ALK protein in patients with ALK-positive ALCL Int J Cancer 118 688-695
  • [9] Yoshioka H(undefined)undefined undefined undefined undefined-undefined
  • [10] Harada M(undefined)undefined undefined undefined undefined-undefined
123456789